Risks to Normal Tissues From Radionuclide Therapy

Seminars in Nuclear Medicine

Volumn 38, Issue 5, 2008, Pages 347-357

  Meredith, Ruby ^a   Wessels, Barry ^b   Knox, Susan ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO 1 PHENYLALANINE 3 TYROSINE OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANETETRAMETHYLENE PHOSPHONIC ACID HO 166; ANTIBODY CONJUGATE Y 90; CD20 ANTIBODY I 131; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY I 125; HOLMIUM 166; IBRITUMOMAB TIUXETAN; IODINE 131; LEVOTHYROXINE SODIUM; MACRO AGGREGATED ALBUMIN P 32; MICROSPHERE; MICROSPHERE Y 90; MONOCLONAL ANTIBODY CC49 LU 177; MONOCLONAL ANTIBODY CC49 Y 90; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; RECOMBINANT THYROTROPIN; RHENIUM 186; TENASCIN MONOCLONAL ANTIBODY 81C6 I 131; THYROTROPIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE HEPATITIS; ACUTE TOXICITY; ALPHA RADIATION; AMENORRHEA; ASEPTIC MENINGITIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BETA RADIATION; BIRTH DEFECT; BLADDER DISEASE; BLADDER IRRIGATION; BONE CANCER; BRAIN INFARCTION; BRAIN NECROSIS; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER RISK; CARDIOTOXICITY; CARDIPULMONARY TOXICITY; CHRONIC HEPATITIS; CHRONIC TOXICITY; COLON CANCER; CONTRACTURE; CREATININE CLEARANCE; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG TOLERABILITY; DRUG TOLERANCE; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FIBROSIS; GAMMA RADIATION; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC CYSTITIS; HISTOGRAM; HUMAN; HYPOTHYROIDISM; INFERTILITY; INTERSTITIAL PNEUMONIA; INTESTINE ULCER; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LUNG CANCER; LUNG TOXICITY; MATHEMATICAL COMPUTING; MICRODOSIMETRY; MYELODYSPLASIA; MYELOMA; NAUSEA; NEPHROSCLEROSIS; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PERICARDITIS; PREDICTION; PROBABILITY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION PNEUMONIA; RADIATION RESPONSE; RADIOISOTOPE THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SECOND CANCER; SEIZURE; SIDE EFFECT; SKIN NECROSIS; SMALL INTESTINE HEMORRHAGE; SMALL INTESTINE PERFORATION; SPERMATOGENESIS; STOMACH CANCER; THEORETICAL MODEL; THROMBOTIC MICROANGIOPATHIC NEPHROPATHY; THYROID CANCER; TOXICITY; UNSPECIFIED SIDE EFFECT; VOMITING; WHOLE BODY RADIATION;

HUMANS; RADIATION INJURIES; RADIATION PROTECTION; RADIOISOTOPES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS;

EID: 47749143991     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.05.001     Document Type: Review

References (136)

1. Meredith R. Clinical trial design and scoring of radionuclide therapy endpoints: Normal organ toxicity and tumor response. Cancer Biother Radiopharm 17 (2002) 83-99
2. Knox S.J., Levy R., Miller R.A., et al. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 50 (1990) 4935-4940
3. Verwijnen S., Capello A., Bernard B., et al. Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948. Cancer Biother Radiopharm 19 (2004) 285-292
4. Neti P.V., and Howell R.W. Log normal distribution of cellular uptake of radioactivity: Implications for biologic responses to radiopharmaceuticals. J Nucl Med 47 (2006) 1049-1058
5. Carlsson J., Eriksson V., Stenerlow B., et al. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy. Eur J Nucl Med Mol Imaging 33 (2006) 1185-1195
6. Bodei L., Cremonesi M., Grana C., et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31 (2004) 1038-1046
7. Abrams P.G., and Fritzberg A.R. Radioimmunotherapy of Cancer (2000), Marcel Dekker, Inc, New York, NY
8. Hagenbeek A. Radioimmunotherapy for NHL: Experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma 44 suppl 4 (2003) S37-S47
9. Blumenthal R.D., Lew W., Juweid M., et al. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 88 (2000) 333-343
10. Martin S., Kronenwett R., Vandenbulcke K., et al. Targeted alpha radiation and gamma rays induce significantly different molecular responses in human leukemic lymphocytes as revealed by gene expression profiling. J Nucl Med 46 suppl 2 (2005) 192
11. Sgouros G., Knox S.J., Joiner M.C., et al. MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?. J Nucl Med 48 (2007) 1683-1691
12. Fowler J.F., and Stern B.E. Dose-rate effects: Some theoretical and practical considerations. Br J Radiol 33 (1960) 389-395
13. Barendsen G.W. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8 (1982) 1981-1997
14. Thames H.D. An 'incomplete-repair' model for survival after fractionated and continuous irradiations. Int J Radiat Biol Relat Stud Phys Chem Med 47 (1985) 319-339
15. Fowler J.F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 18 (1990) 1261-1269
16. Langmuir V.K., Fowler J.F., Knox S.J., et al. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 20 (1993) 601-610
17. Dale R.G. Dose-rate effects in targeted radiotherapy. Phys Med Biol 41 (1996) 1871-1884
18. O'Donoghue J.A. Optimal therapeutic strategies for radioimmunotherapy. Recent Results Cancer Res 141 (1996) 77-99
19. Howell R.W., Goddu S.M., and Rao D.V. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Med Phys 25 (1998) 37-42
20. Yorke E.D., Wessels B.W., and Bradley E.W. Absorbed dose averages and dose heterogeneities in Radioimmunotherapy. Antibody Immunoconjugates and Radiopharmaceuticals 4 (1991) 623-629
21. Thames H., and Hendry J.H. Fractionation in Radiotherapy (1987), Taylor and Francis, London
22. Kassis A.I., and Adelstein S.J. Radiobiologic principles in radionuclide therapy. J Nucl Med 1 suppl 46 (2005) 4S-12S
23. Sgouros G. Dosimetry of internal emitters. J Nucl Med 46 suppl 1 (2005) 18S-27S
24. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 19 (2004) 363-370
25. Brenner D.J., Hlatky L.R., Hahnfeldt P.J., et al. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res 150 (1998) 83-91
26. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 58 (1985) 515-528
27. Guerrero M., and Li X.A. Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49 (2004) 4825-4835
28. Song D.Y., Kavanagh B.D., Benedict S.H., et al. Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park) 18 (2004) 1419-1430 discussion 1430, 1432:1435-1416
29. Ruben J.D., Dally M., Bailey M., et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65 (2006) 499-508
30. Brill A.B., Stabin M., Bouville A., et al. Normal organ radiation dosimetry and associated uncertainties in nuclear medicine, with emphasis on iodine-131. Radiat Res 166 (2006) 128-140
31. Mothersill C., and Seymour C. Low-dose radiation effects: experimental hematology and the changing paradigm. Exp Hematol 31 (2003) 437-445
32. Mothersill C., and Seymour C. Radiation-induced bystander effects, carcinogenesis and models. Oncogene 22 (2003) 7028-7033
33. Bouchard V.J., Rouleau M., and Poirier G.G. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31 (2003) 446-454
34. Albanese J., and Dainiak N. Modulation of intercellular communication mediated at the cell surface and on extracellular, plasma membrane-derived vesicles by ionizing radiation. Exp Hematol 31 (2003) 455-464
35. Boyd M., Ross S.C., Dorrens J., et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med 47 (2006) 1007-1015
36. Davidson S.E., Trotti A., Ataman O.U., et al. Improving the capture of adverse event data in clinical trials: The role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 69 (2007) 1218-1221
37. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
38. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
39. Einstein A.J., Henzlova M.J., and Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 298 (2007) 317-323
40. Tronko M.D., Howe G.R., Bogdanova T.I., et al. A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst 98 (2006) 897-903
41. Kry S.F., Salehpour M., Followill D.S., et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 1195-1203
42. Rubino C., Adjadj E., Doyon F., et al. Radiation exposure and familial aggregation of cancers as risk factors for colorectal cancer after radioiodine treatment for thyroid carcinoma. Int J Radiat Oncol Biol Phys 62 (2005) 1084-1089
43. Bal C., Kumar A., Tripathi M., et al. High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. Int J Radiat Oncol Biol Phys 63 (2005) 449-455
44. Subramanian S., Goldstein D.P., Parlea L., et al. Second primary malignancy risk in thyroid cancer survivors: A systematic review and meta-analysis. Thyroid 17 (2007) 1277-1288
45. Brown J.R., Yeckes H., Friedberg J.W., et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 2208-2214
46. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
47. Bennett J.M., Kaminski M.S., Leonard J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105 (2005) 4576-4582
48. Rubin P., and Casarett G.W. A direction for clinical radiation pathology: A tolerance dose. In: Vaeth J.M. (Ed). Frontiers of Radiation Oncology and Therapy Vol. 6 (1972), University Park Press, Baltimore, MD 1-16
49. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
50. Sarfaraz M., Kennedy A.S., Lodge M.A., et al. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys 31 (2004) 2449-2453
51. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 8 (1985) S13-S19
52. Lyman J.T., and Wolbarst A.B. Optimization of radiation therapy, IV: A dose-volume histogram reduction algorithm. Int J Radiat Oncol Biol Phys 17 (1989) 433-436
53. Milano M.T., Constine L.S., and Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 17 (2007) 131-140
54. Mundt A., and Roeske J. Intensity Modulated Radiation Therapy: A Clinical Perspective (2005), BC Decker, Inc, Hamilton, ON
55. Dawson L.A., Biersack M., Lockwood G., et al. Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. Int J Radiat Oncol Biol Phys 62 (2005) 829-837
56. Glatstein E. Personal thoughts on normal tissue tolerance, or, what the textbooks don't tell you. Int J Radiat Oncol Biol Phys 51 (2001) 1185-1189
57. Cheng J.C., Liu H.S., Wu J.K., et al. Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. Int J Radiat Oncol Biol Phys 62 (2005) 1150-1156
58. Zhou S.D., Yan H., Zeng J., et al. Marks Identification of predictors of RT-induced toxicity with the Random Forests Technique. Int J Radiat Oncol Biol Phys 66 (2006) 519s
59. Bodey R.K., Evans P.M., and Flux G.D. Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys 59 (2004) 228-241
60. Yorke E.D., Jackson A., Fox R.A., et al. Can current models explain the lack of liver complications in Y-90 microsphere therapy?. Clin Cancer Res 5 (1999) 3024s-3030s
61. Andrews J.C., Walker S.C., Ackermann R.J., et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med 35 (1994) 1637-1644
62. Tempero M., Leichner P., Baranowska-Kortylewicz J., et al. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: A phase I trial. Clin Cancer Res 6 (2000) 3095-3102
63. Kennedy A.S., Nutting C., Coldwell D., et al. Pathologic response and microdosimetry of (90)Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60 (2004) 1552-1563
64. Order S.E., Siegel J.A., Principato R., et al. Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: A phase I study. Int J Radiat Oncol Biol Phys 36 (1996) 1117-1126
65. Wessels B.W., Yorke E.D., and Bradley E.W. Dosimetry of heterogeneous uptake of radiolabeled antibody for radioimmunotherapy. Front Radiat Ther Oncol 24 (1990) 104-108 discussion 121-102
66. Schefter T.E., Kavanagh B.D., Timmerman R.D., et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 62 (2005) 1371-1378
67. Neff R., Abdel-Misih R., Khatri J., et al. The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. Cancer Invest 26 (2008) 173-177
68. Reardon D.A., Akabani G., Coleman R.E., et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 (2002) 1389-1397
69. Riva P., Franceschi G., Frattarelli M., et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study. Clin Cancer Res 5 (1999) 3275s-3280s
70. Akabani G., Reardon D.A., Coleman R.E., et al. A phase II study of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: Dosimetry and radiographic analysis. Supplement to The Journal of Nuclear Medicine-Abstract Book. Supplement 2 edition Vol. 46 (2005), Society of Nuclear Medicine, Inc, Reston, VA 446P
71. Zalutsky M.R., Reardon D.A., Akabani G., et al. Clinical experience with {alpha}-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49 (2008) 30-38
72. Shaw E., Scott C., Souhami L., et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47 (2000) 291-298
73. Korytko T., Radivoyevitch T., Colussi V., et al. 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors. Int J Radiat Oncol Biol Phys 64 (2006) 419-424
74. Gutierrez A.N., Westerly D.C., Tome W.A., et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: A planning study. Int J Radiat Oncol Biol Phys 69 (2007) 589-597
75. Flickinger J.C.K.D., and Lunsford L.D. Dose and diameter relationships for facial, trigeminal and acoustic neuropathies following acoustic neuroma radiosurgery. Radiother Oncol 41 (1996) 215-219
76. Knox S.J., Goris M.L., Tempero M., et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6 (2000) 406-414
77. Melis M., Krenning E.P., Bernard B.F., et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 32 (2005) 1136-1143
78. de Jong M., Breeman W.A., Valkema R., et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 1 suppl 46 (2005) 13S-17S
79. Bolch W.E., Bouchet L.G., Robertson J.S., et al. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 40 (1999) 11S-36S
80. Bouchet L.G., Bolch W.E., Blanco H.P., et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 44 (2003) 1113-1147
81. Bouchet L.G., Bolch W.E., Weber D.A., et al. MIRD Pamphlet No. 15: Radionuclide S values in a revised dosimetric model of the adult head and brain. Medical Internal Radiation Dose. J Nucl Med 40 (1999) 62S-101S
82. Howell R.W., Wessels B.W., Loevinger R., et al. The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med 40 (1999) 3S-10S
83. Valkema R., Pauwels S.A., Kvols L.K., et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 1 suppl 46 (2005) 83S-91S
84. Barone R., Borson-Chazot F., Valkema R., et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 1 suppl 46 (2005) 99S-106S
85. Breitz H. Dosimetry in a myeloablative setting. Cancer Biother Radiopharm 17 (2002) 119-128
86. George J.N. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol 3 (2005) 627-632
87. Akabani G., Cokgor I., Coleman R.E., et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46 (2000) 947-958
88. Paganelli G., Zoboli S., Cremonesi M., et al. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm 14 (1999) 477-483
89. Pizer B.L., Papanastassiou V., Moseley R., et al. Meningeal leukemia and medulloblastoma: Preliminary experience with intrathecal radioimmunotherapy. Antibody Immunoconj Radiopharm 4 (1991) 753
90. Riva P., Arista A., Tison V., et al. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer 73 (1994) 1076-1082
91. Paganelli G., Grana C., Chinol M., et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26 (1999) 348-357
92. Riva P., Arista A., Franceschi G., et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: Comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55 (1995) 5952s-5956s
93. Richardson R.B., Kemshead J.T., Davies A.G., et al. Dosimetry of intrathecal iodine131 monoclonal antibody in cases of neoplastic meningitis. Eur J Nucl Med 17 (1990) 42-48
94. Brown M.T., Coleman R.E., Friedman A.H., et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 2 (1996) 963-972
95. Kemshead J.T., Hopkins K., Pizer B., et al. Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies. Br J Cancer 77 (1998) 2324-2330
96. Nieder C., Grosu A.L., Andratschke N.H., et al. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys 66 (2006) 1446-1449
97. Wahl R.L. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med 46 suppl 1 (2005) 128S-140S
98. Liu S.Y., Eary J.F., Petersdorf S.H., et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16 (1998) 3270-3278
99. Bal C.S., Kumar A., and Pant G.S. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89 (2004) 1666-1673
100. Hanscheid H., Lassmann M., Luster M., et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47 (2006) 648-654
101. Press O.W., Eary J.F., Appelbaum F.R., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329 (1993) 1219-1224
102. Chiesa C., Botta F., Di Betta E., et al. Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: Possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm 22 (2007) 113-120
103. Breitz H.B., Weiden P.L., Vanderheyden J.L., et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 33 (1992) 1099-1109
104. Matthews D.C., Appelbaum F.R., Eary J.F., et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 94 (1999) 1237-1247
105. Carabasi M., Khazaeli M.B., Tilden A.B., et al. Autologous stem cell transplantation for breast and prostate cancer after combined modality therapy with radioimmunotherapy plus external beam radiation. Blood 94 (1999) 333a
106. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41 (2000) 1673-1681
107. Yu C.X., Hisley C., and Kennedy A. tumor volume-based prescription for the treatment of liver cancer with micro-sphere infusion. Int J Radiat Oncol Biol Phys 54 (2002) 126-127
108. Breitz H.B., Fisher D.R., Goris M.L., et al. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 14 (1999) 381-395
109. Epenetos A.A., Courtenay-Luck N., Dhokia B., et al. Antibody-guided irradiation of hepatic metastases using intrahepatically administered radiolabelled anti-CEA antibodies with simultaneous and reversible hepatic blood flow stasis using biodegradable starch microspheres. Nucl Med Commun 8 (1987) 1047-1058
110. Stewart J.S., Hird V., Snook D., et al. Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 16 (1989) 405-413
111. Raymond J.P., Izembart M., Marliac V., et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 69 (1989) 186-190
112. Pacini F., Gasperi M., Fugazzola L., et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 35 (1994) 1418-1422
113. Meredith R., Alvarez R.D., Khazaeli M.B., et al. Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177 Lu-CC49. Minerva Biotechnol 10 (1998) 100-107
114. Liu T., Meredith R.F., Saleh M.N., et al. Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm 12 (1997) 79-87
115. Weiden P.L., Breitz H.B., Press O., et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm 15 (2000) 15-29
116. Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (1996) 457-470
117. Williams G., Palmer M.R., Parker J.A., et al. Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report. Cancer Biother Radiopharm 21 (2006) 101-105
118. Bradley J.D., Paulus R., Graham M.V., et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: Promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23 (2005) 3480-3487
119. Fisher D., Rajon D., Breitz H., et al. Dosimetry model for radioactivity localized to intestinal mucosa. Cancer Biother Radiopharm 19 (2004) 293-307
120. Spanos Jr. W.J., Day T., Abner A., et al. Complications in the use of intra-abdominal 32P for ovarian carcinoma. Gynecol Oncol 45 (1992) 243-247
121. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 19 (2004) 378-387
122. Meredith R.F., Khazaeli M.B., Plott G., et al. Comparison of diagnostic and therapeutic doses of 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconj Radiopharm 6 (1993) 1
123. Macey D.J., Grant E.J., Kasi L., et al. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial. Clin Cancer Res 3 (1997) 1547-1555
124. Clarke K.G., Odom-Maryon T.L., Williams L.E., et al. Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy. Med Phys 26 (1999) 799-809
125. Eary J.F., Pollard K.R., Durack L.D., et al. Post therapy imaging in high dose I-131 radioimmunotherapy patients. Med Phys 21 (1994) 1157-1162
126. Hartmann Siantar C.L., DeNardo G.L., and DeNardo S.J. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med 44 (2003) 1322-1329
127. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
128. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 672-682
129. Bradley J.D., Hope A., El Naqa I., et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 69 (2007) 985-992
130. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63 (2005) 5-24
131. Chang B.K., and Timmerman R.D. Stereotactic body radiation therapy: A comprehensive review. Am J Clin Oncol 30 (2007) 637-644
132. Ho A.Y., Fan G., Atencio D.P., et al. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 69 (2007) 677-684
133. Couturier O., Supiot S., Degraef-Mougin M., et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging 32 (2005) 601-614
134. Bruland O.S., Nilsson S., Fisher D.R., et al. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities?. Clin Cancer Res 12 (2006) 6250s-6257s
135. Jurcic J. Alpha-particle Immunotherapy for acute myeloid leukemia (AML) with Bismuth-213 and Actinium-225. Cancer Biother Radiopharm 21 (2006) 396
136. Quang T.S., and Brady L.W. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys 58 (2004) 972-975